FI3891156T3 - Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia - Google Patents

Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia Download PDF

Info

Publication number
FI3891156T3
FI3891156T3 FIEP19817229.8T FI19817229T FI3891156T3 FI 3891156 T3 FI3891156 T3 FI 3891156T3 FI 19817229 T FI19817229 T FI 19817229T FI 3891156 T3 FI3891156 T3 FI 3891156T3
Authority
FI
Finland
Prior art keywords
compound
cancer
crystalline form
theta
degrees
Prior art date
Application number
FIEP19817229.8T
Other languages
English (en)
Finnish (fi)
Inventor
Baets Emilie De
Julien Auvray
Michael Lynch
Nicolas Leblanc
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Application granted granted Critical
Publication of FI3891156T3 publication Critical patent/FI3891156T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP19817229.8T 2018-12-06 2019-12-05 Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia FI3891156T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (1)

Publication Number Publication Date
FI3891156T3 true FI3891156T3 (fi) 2024-02-07

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19817229.8T FI3891156T3 (fi) 2018-12-06 2019-12-05 Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia

Country Status (26)

Country Link
US (2) US12129261B2 (https=)
EP (1) EP3891156B1 (https=)
JP (1) JP7649241B2 (https=)
KR (1) KR102855345B1 (https=)
CN (1) CN113166169A (https=)
AR (1) AR117255A1 (https=)
AU (1) AU2019391329B2 (https=)
BR (1) BR112021010072A2 (https=)
CA (1) CA3121363A1 (https=)
DK (1) DK3891156T3 (https=)
EA (1) EA202191534A1 (https=)
ES (1) ES2971258T3 (https=)
FI (1) FI3891156T3 (https=)
HR (1) HRP20240211T1 (https=)
HU (1) HUE065266T2 (https=)
IL (1) IL283656B2 (https=)
LT (1) LT3891156T (https=)
MA (1) MA54379B1 (https=)
MD (1) MD3891156T2 (https=)
MX (1) MX2021006702A (https=)
PL (1) PL3891156T3 (https=)
PT (1) PT3891156T (https=)
RS (1) RS65047B1 (https=)
SI (1) SI3891156T1 (https=)
TW (1) TWI905090B (https=)
WO (1) WO2020115183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2020115183A1 (en) 2020-06-11
SI3891156T1 (sl) 2024-03-29
KR20210100148A (ko) 2021-08-13
EA202191534A1 (ru) 2021-10-27
KR102855345B1 (ko) 2025-09-03
PL3891156T3 (pl) 2024-05-13
TWI905090B (zh) 2025-11-21
HRP20240211T1 (hr) 2024-04-26
MA54379A (fr) 2021-10-13
BR112021010072A2 (pt) 2021-08-24
CN113166169A (zh) 2021-07-23
JP7649241B2 (ja) 2025-03-19
US20220017533A1 (en) 2022-01-20
EP3891156B1 (en) 2023-11-15
MD3891156T2 (ro) 2024-06-30
AU2019391329A1 (en) 2021-07-01
LT3891156T (lt) 2023-12-27
DK3891156T3 (da) 2024-02-19
EP3891156A1 (en) 2021-10-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
IL283656B2 (en) 2025-10-01
ES2971258T3 (es) 2024-06-04
IL283656A (en) 2021-07-29
CA3121363A1 (en) 2020-06-11
JP2022511495A (ja) 2022-01-31
MX2021006702A (es) 2021-07-07
MA54379B1 (fr) 2023-12-29
HUE065266T2 (hu) 2024-05-28
NZ776907A (en) 2025-05-02
AU2019391329B2 (en) 2024-09-26
US20250011337A1 (en) 2025-01-09
RS65047B1 (sr) 2024-02-29
US12129261B2 (en) 2024-10-29
AR117255A1 (es) 2021-07-21
PT3891156T (pt) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
JP6322770B2 (ja) Ｅｒｋ阻害剤
RU2631240C2 (ru) Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
MX2022008066A (es) Compuestos triciclicos sustituidos.
KR102534266B1 (ko) 헤테로환형 유도체 및 이의 용도
PH12022551014A1 (en) Substituted tricyclic compounds
RU2612251C2 (ru) Соединения диоксин- и оксазин[2,3-d]пиримидина в качестве ингибиторов фосфоинозитид-3-киназы и способы их применения
JP2021515010A5 (https=)
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
JP2018522879A5 (https=)
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
RU2018102365A (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
JP2014513704A5 (https=)
JP6333996B2 (ja) がんを予防または治療するための、ブロモドメイン阻害化合物およびそれを含む医薬組成物
RU2021132394A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
JP2015522551A5 (https=)
FI3891156T3 (fi) Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
SI3174881T1 (en) (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases
JP2022511495A5 (https=)
WO2019129114A1 (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
RU2021119029A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
NZ776907B2 (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.
RU2023135057A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
NZ775308B2 (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same